Korro Bio, Inc. (KRRO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$16.62+4.79%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · KRRO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 62.4% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| -88.5% |
Growth built into the price is above our model estimate.
The price assumes 150.9 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 66 industry peers
KRRO — M&A activity — Termination of a Material Definitive Agreement
Dated 2026-11-05
Termination of a Material Definitive Agreement. On November 3, 2026, Korro Bio, Inc., or Korro, received written notice from Novo Nordisk A/S, or Novo Nordisk, of Novo Nordisk’s election to terminate for convenience the research collaboration and license agreement between Korro and Novo Nordisk dated September 13, 2024, as amended on November 11, 2025, or the collaboration and license agreement. Under the collaboration and license agreement, Novo Nordisk may terminate the agreement without ca…
Why it matters: The filing is the next step toward human testing of KRRO-111. Its current evidence comes from preclinical studies, not people.
Supportive ifKorro submits the KRRO-111 regulatory package by June 30, 2027, and reports plans to start a clinical trial.
Worry ifKorro delays the filing past June 30, 2027, or reports a preclinical or safety issue that blocks it.
Why it matters: The trial would move KRRO-121 from animal studies into human testing. Korro has said the first trial would start in the second half of 2026.
Supportive ifA company update or trial record confirms the first patient received a KRRO-121 dose by December 31, 2026.
Worry ifKorro reports that the first dose is delayed beyond 2026, or the trial has not started by year-end.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$268 on $10,000 · ±2.7% | How much price usually moves either way. |
| Bad day | $746 loss on $10,000 · 7.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,440 loss on $10,000 · 84.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.